CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← OTSUKA (OTSKF) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

OTSUKA (OTSKF)

Healthcare · market cap $38.8B · as of 2026-07-09

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2027-02-24 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
7
next 90d+
Dossier
Ready
cached
Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.
Otsuka Holdings (OTSKF) is a large-cap Japanese healthcare conglomerate with approximately 35,338 employees and a market cap of ~$34 billion. The company operates a broad, multi-therapeutic pipeline spanning psychiatry, nephrology, oncology, dermatology, and rare disease, with several Phase 3 assets near read-out. Key near-term catalysts include Phase 3 data for SEP-363856 (schizophrenia) in October 2026, JNT-517 (PKU) in November 2026, and the BPaQM TB regimen in May 2027.
The catalyst path
  • 2027-02-24 (est.)Phase 2 · Bedaquiline (B)imp 7/10
  • 2027-03-13 (est.)Phase 2 · Sibeprenlimabimp 7/10
  • 2027-05-15 (est.)Phase 2 · IRL757imp 7/10
  • 2027-05-27 (est.)Phase 3 · Centanafadine XRimp 9/10
  • 2027-08-15 (est.)Phase 3 · EB-1020 (Centanafadine) low doseimp 9/10
  • 2027-09-15 (est.)Phase 3 · OPC-34712FUM/Brexpiprazole fumarateimp 9/10
  • 2027-11-01 (est.)Phase 3 · JNT-517imp 9/10
Pipeline
AssetPhaseIndication
Medium Dose-VIS649Phase 2Immunoglobulin A Nephropathy
Paroxetine CRPhase 3Depressive Disorder
OPB-31121 phase2Phase 2Hepatocellular Carcinoma
Centanafadine XRPhase 3Attention-deficit/Hyperactivity Disorder
Graft versus Host Disease prevention (GVHD prophylaxis)Phase 2Hematological Malignancies
Brexpiprazole, OPC-34712Phase 3Agitation Associated With
Venlafaxine XRPhase 3Depressive Disorder
ClofaziminePhase 2Tuberculosis, Multidrug-Resistant
High Dose-VIS649Phase 2Immunoglobulin A Nephropathy
OCV-501Phase 2Acute Myeloid Leukemia
JNT-517 TabletPhase 3Phenylketonuria (PKU)
Sodium hyaluronate ophthalmic solutionPhase 2Keratoconjunctival Epithelial Disorder
Delamanid + Bedaquiline + OPC-167832Phase 2Pulmonary TB
centanafadine capsulePhase 3Attention Deficit/Hyperactivity Disorder
ProbucolPhase 3Hyperlipidemia
Centanafadine HydrochloridePhase 3Attention-Deficit/Hyperactivity Disorder
Tolvaptan Oral TabletPhase 3Syndrome of Inappropriate Antidiuretic Hormone Secretion
OPB-31121Phase 2Hepatocellular Carcinoma
OPC-64005Phase 2Adult Attention Deficit Hyperactivity Disorder
OPC-41061 (Tolvaptan)Phase 3Cardiac Edema
Price & technical context
3-month
-5.6%
6-month
+13.3%
12-month
+26.7%
52-wk range
$54.26–$77.53
vs 50-day MA
-0.7%
vs 200-day MA
+5.5%
Realized vol
26.6%
Max drawdown
-32.9%

Daily closes through 2026-11-13. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for OTSKF (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.